Why the study?
The study sought to compare the 1-year safety and effectiveness of rivaroxaban 15 mg or 20 mg with vitamin K antagonists in nonvalvular atrial fibrillation.
Does rivaroxaban 15 mg or 20 mg reduce stroke, systemic embolism, major bleeding, and death compared to vitamin K antagonists in patients with nonvalvular atrial fibrillation?
Does rivaroxaban 15 mg or 20 mg reduce stroke, systemic embolism, major bleeding, and death compared to vitamin K antagonists in patients with nonvalvular atrial fibrillation?
In a large real-world cohort, rivaroxaban 15 mg and 20 mg were associated with similar or lower rates of stroke, major bleeding, and death compared to vitamin K antagonists in patients with nonvalvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Rivaroxaban 20 mg was associated with lower stroke and bleeding rates vs VKA in real-world AF; extends RCT findings but leaves practice implications open pending randomized data.
Background and Purpose— We compared the 1-year safety and effectiveness of rivaroxaban 15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with nonvalvular atrial fibrillation. Methods— New user cohort study of patients dispensed R15 or R20 versus VKA in 2013 or 2014 for nonvalvular atrial fibrillation, followed 1 year in the French Système National des Données de Santé (66 million people). R15 and R20 users were matched 1:1 with VKA users on sex, age, date of first drug dispensing, and high-dimensional propensity score. Hazard ratios (95% CIs) for stroke and systemic embolism, major bleeding, and death were computed using Cox proportional hazards or models by Fine and Gray during exposure. Results— In 31 171 matched R20 and VKA, mean age, 71; 62% men; 76% with CHA 2 DS 2 -VASc ≥2; 5% HAS-BLED >3 (hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, elderly, drugs or alcohol); incidence rates for stroke and systemic embolism were 1.5% and 1.9% (hazard ratio, 0.79 [0.69–0.90]); major bleeding, 1.5% and 2.2% (0.67 [0.59–0.77]); death, 3.9% and 5.8% (0.67 [0.61–0.73]). In 23 314 matched R15 and VKA patients, mean age, 80; 47% men; 93% with CHA 2 DS 2 -VASc ≥2 and 9% with HAS-BLED >3; incidence rates of stroke and systemic embolism were 2.3% and 2.1% (1.05 [0.92–1.21]); major bleeding, 2.4% and 2.9% (0.84 [0.74–0.96]); death, 9.1% and 10.8% (0.85 [0.79–0.90]). Numbers needed to treat to observe one fewer death (NNT) were 46 for R15 and 61 for R20. Conclusions— In real life in France over 2013 to 2015, R15 and R20 were at least as effective and safer than VKA. Clinical Trial Registration— URL: http://www.encepp.eu . Unique identifier: EUPAS14567.
No takes yet. Share an insight, caveat, or question.
Blin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: